icosapent ethyl
Generic: ICOSAPENT ETHYL·Brand: ICOSAPENT ETHYL, VASCEPA
icosapent ethyl: developed by 1 company.
icosapent ethyl evidence translation
What we can confirm
No verified FDA or trial count is available.
What it means
Source-backed records connect icosapent ethyl to AMRN; that link alone does not prove the drug works.
What to watch
Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected
Prepared research question
How could icosapent ethyl → AMRN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
MARINE indication: adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia; REDUCE-IT indication: adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (≥150 mg/dL) and either established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.Reducing triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia; reducing persistent cardiovascular risk in select high-risk patients as an adjunct to maximally tolerated statin therapy.Reduction of triglyceride levels in adult patients with severe hypertriglyceridemia; reduction of persistent cardiovascular risk in select high-risk patients
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (3)
| Company | Phase |
|---|---|
| AMARIN CORP PLCUK (AMRN) MARINE indication: adjunct to diet to reduce triglyceride le… | Approved |
| AMARIN CORP PLCUK (AMRN) Reducing triglyceride levels in adult patients with severe (… | Approved |
| AMARIN CORP PLCUK (AMRN) Reduction of triglyceride levels in adult patients with seve… | Approved |